07:00 Wed 20 Nov 2019
Advanced Oncotherapy - Subscription to raise c.GBP 2.7 million
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement via a
("
Subscription to raise c.
A total of 6,825,000 new ordinary shares of
Application will be made to the
Application will be made to the
Total voting rights
Upon First Admission, the Company's enlarged issued share capital will comprise 243,842,656 Ordinary Shares, with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares in the Company with voting rights will be 243,842,656.
Upon Second Admission, the Company's enlarged issued share capital will comprise of 244,423,406 Ordinary Shares, with voting rights. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares in the Company with voting rights will be 244,423,406.
These figures may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
- ENDS -
|
|
Dr. Michael Sinclair, Executive Chairman |
Tel: +44 (0) 20 3617 8728 |
Nicolas Serandour, CEO |
|
|
|
|
|
Nick Athanas / Liz Kirchner / Nicholas Chambers |
Tel: +44 (0) 20 7601 6100 |
|
|
|
|
Simon Conway / Rob Winder |
Tel: +44 (0) 20 3727 1000 |
Notes for Editors
About
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE